Abstract：【Objective】To compare the clinical efficacy and their impact on patients' cognitive function of lurasidone and olanzapine in the treatment of schizophrenia.【Methods】A total of 116 patients with schizophrenia admitted to Baoshan District Mental Health Center in Shanghai from August 2020 to December 2023 were selected and randomly divided into two groups using a random number table: the lurasidone group and the olanzapine group, with 58 patients in each group. Both groups of patients were treated for 12 weeks, and their clinical symptom improvement, cognitive function, biochemical indicators of neurological function [nerve growth factor (NGF), gamma aminobutyric acid (GABA), specific enolase (NSE)], inflammatory and metabolic indicators [interleukin-4 (IL-4), interleukin-8 (IL-8), triglycerides (TG), body mass index (BMI)], and incidence of adverse reactions were compared. 【Results】The scores of the Negative and Positive Symptom Scale (PANSS) in both groups were lower than those before treatment, and the PANSS scores in the lurasidone group were lower than those in the olanzapine group, with statistically significant differences (P<0.05). At the 4th and 12th week of treatment, the MCCB scores of both groups were higher than those before treatment, and the MCCB score of the lurasidone group was higher than that of the olanzapine group, with statistical significance (P<0.05). After treatment, the levels of serum NGF and GABA in both groups were higher than those before treatment, and the levels of serum NGF and GABA in the lurasidone group were higher than those in the olanzapine group, with statistical significance (P<0.05). The serum NSE levels in both groups were lower than those before treatment, and the level in the lurasidone group was lower than that in the olanzapine group, with statistically significant difference (P<0.05). After treatment, the average levels of IL-4 and IL-8 in the serum of both groups were lower than those before treatment. The levels of IL-4 and IL-8 in the lurasidone group were lower than those in the olanzapine group. The BMI and TG in the lurasidone group were lower than before treatment and both BMI and TG were lower than those in the olanzapine group, with statistical significance (P<0.05); After treatment, there was no statistically significant difference in BMI and TG in the olanzapine group if compared to before treatment (P>0.05). The total incidence of adverse reactions in the lurasidone group was 8.62% (5/58), which was lower than the 24.14% (14/58) in the olanzapine group, and the difference was statistically significant (P=0.024). 【Conclusion】Lurasidone can improve cognitive function, reduce levels of inflammatory factors, and not increase the risk of metabolic disorders in patients with schizophrenia. It has a low incidence of adverse reactions and good safety.
李公权, 曹琳佳, 谢清芳. 比较鲁拉西酮与奥氮平治疗精神分裂症的临床效果及对患者认知功能的影响[J]. 医学临床研究, 2025, 42(3): 437-440.
LI Gongquan, CAO Linjia, XIE Qingfang. Comparison of the Clinical Efficacy and Impact on Cognitive Function of Lorazepine and Olanzapine in the Treatment of Schizophrenia. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 437-440.
2025, Vol. 42 
